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Available online 25 April 2008Programmed Death-1 (PD-1), a member of T cell costimulatory molecules is expressed in high levels on
antigen speciﬁc T cells during chronic viral infection, whereas PD-1 expression in the context of HIV-1
infected CD4+ T cells is not known. Here we report that productively infected CD4+ T cells lose PD-1,
whereas bystander cells were unaffected. Additionally, p24+/PD-1 negative cells are less susceptible to
apoptosis compared to bystander cells in the same infected milieu. Similar results were observed in vivo,
as infected T cells isolated from HIV-1+ individuals have signiﬁcantly low level of PD-1 and the observed
loss of PD-1 in vivo is independent of viral load, CD4 count, and/or antiviral treatment. Together these
results indicate that productively infected cells are resistant to early apoptosis by downregulating PD-1,
whereas PD-1 enhances the susceptibility of effector T cells to apoptosis suggesting a dual role for PD-1
during HIV-1 infection.
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The Programmed Death-1 (PD-1) molecule, a member of the B7
family of costimulatory molecules plays a key role in the regulation of
T cell activation, autoimmunity, tolerance and apoptosis (Greenwald
et al., 2005; Zha et al., 2004). PD-1 is an inhibitory molecule that is
induced upon TCR ligation and expressed on activated T cells, B cells,
NKT cells and activated monocytes (Meng et al., 2006; Nielsen et al.,
2005). Recent studies report that expression of PD-1 is high in virus
speciﬁc CD8+ cells in HIV-1 and HCV positive patients and these cells
exhibit an exhausted phenotype (Barber et al., 2006; Petrovas et al.,
2006; Trautmann et al., 2006; Zhang et al., 2007). Additionally, these
cells are more susceptible to activation-induced and/or other apop-
totic pathways suggesting that PD-1 positive cells are eliminated
in vivo through several mechanisms (Freeman et al., 2006). Blocking
the PD-1: PD-L1 (PD-Ligand 1) pathway in antigen speciﬁc CD8+
T cells using PD-L1 antibody enhanced their ability to proliferate in
response to HIV-1 antigen (Day et al., 2006; Freeman et al., 2006;
Grakoui et al., 2006).
During HIV-1 infection both CD4+ and CD8+ T cells are depleted in
signiﬁcant amounts and this loss is not speciﬁc to infected cell
population (Cotton et al., 1996; Holm and Gabuzda, 2005; Mehandru
et al., 2004; Varbanov, Espert, and Biard-Piechaczyk, 2006). Both viral
and host cellular factors are known to play a role in T cell depletionl rights reserved.during HIV-1 infection (Azad, 2000; Moon and Yang, 2006). More
importantly, infected cells are protected from apoptosis as a means to
aid virus production and dissemination, whereas, bystander cells are
targeted for apoptosis (Carbonari et al., 1997; Conti et al., 1998; Finkel
et al., 1995; Lelievre et al., 2004). Although role of PD-1 in HIV-1
antigen speciﬁc T cells (CD4 and CD8) is established, PD-1 expression
in the context of infected T cells is not known. Using normal donor
primary peripheral mononuclear cells (PBMC), and HIV-1-EGFP
reporter virus, we assessed PD-1 expression on HIV-1 infected and
bystander T cells. Results indicate that productively infected T cells
selectively lose PD-1 expression, whereas, uninfected cells were not
affected. Furthermore, PD-1−/EGFP+ cells were resistant to apoptosis
compared to PD-1+/EGFP− cells.
To understand whether a similar phenomenon occurs in vivo, we
extended our analysis in infected T cells isolated from HIV-1 positive
individuals. Similar to our in vitro observations, HIV-1 patients' lym-
phocytes that are positive for HIV-1 p24 did not express detectable
level of PD-1, whereas uninfected bystander cells expressed PD-1.
Downregulation of PD-1 in infected cells in vivo is independent of viral
load, basal level of host cellular PD-1 expression and/or antiviral the-
rapy. Furthermore, the p24 positive cells also expressed a high level of
anti-apoptotic protein, Bcl-2, suggesting that virus infection in early
stages might protect the infected cells from virus-induced and/or
activation-induced cell death through PD-1 downregulation, whereas
antigen speciﬁc T cells are exhausted. Together these results indicate
that HIV-1 infection differentially regulates PD-1 expression and pro-
tect the infected cells from apoptosis during early infection as a
mechanism to maximize virus production.
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Downregulation of PD-1 in HIV-1 infected culture
In HIV-1 infected patients, antigen speciﬁc T cells (both CD4 and
CD8) are known to express a high level of PD-1. However, in the context
of infection the level of PD-1 expression is unknown. Therefore, ﬁrst
we evaluated the PD-1 expression level in HIV-1 infected and
uninfected culture from the same donor. To address the expression
pattern of PD-1 within the infected culture, PHA-P or anti-CD3/anti-
CD28 stimulated PBMC were infected with 0.01 MOI of HIV-1-EGFP
virus as described (Venkatachari, Majumder, and Ayyavoo, 2007). Live
CD3+ cells were gated (shown in Fig. 1) and PD-1 expression was
evaluated on both CD4+ and CD8+ populations on day 5 postinfection.
Results indicate that there is a 50% loss of PD-1 expression in CD4+ cells
in the infected culture (9.7%) compared to CD4+ cells in the uninfected
culture (17.2%), whereas, PD-1 level in CD8+ T cells within these two
cultures are unaffected (Fig. 1A). Next, to understand the time kinetics
involved in PD-1 dysregulation, we assessed PD-1 expression pre and
postinfection. Expression of PD-1 in unactivated T cells on day 0 was
b5% and activation with anti-CD3/anti-CD28 or PHA-P increased PD-1
up to 20% on day 3 (data not shown). Three days postinfection there
was a signiﬁcant loss in PD-1within the infected culture and this loss is
maintainedup to9 days. This directly correlatedwith the percentage of
infected cells (based on EGFP+) present in the culture suggesting that
productive infection is required for PD-1 loss and virus binding/entry
does not alter PD-1 expression.
Next, to validate the above ﬁnding, we treated activated PBMCwith
AT-2 treated inactivated virus that is not defective in binding or entry
and assessed PD-1 level in CD4+ cells (Fig. 1C). Results indicate level of
PD-1 in CD4+ T cells remained similar to uninfected culture, whereas,
a signiﬁcant loss was observed in PBMC infected with replication
competent virus. Collectively, these results indicate that loss of PD-1 in
the infected culture is due to productive infection and not due to virus
binding, entry and/or exposure to virion-associated HIV-1 proteins.
Productively infected CD4+ target cells lose PD-1 expression
Results above indicate that CD4+ cells lose PD-1 within the
infected culture. Next to identify whether this effect is seen
speciﬁcally in the infected cells, 3 days postinfection, live CD3+
cells were gated and PD-1 expression was assessed within the
infected (EGFP+) and bystander (EGFP−) population by ﬂow cyto-
metry. Results indicate that cells that are productively infected (based
on EGFP expression) with HIV-1 are negative for PD-1 expression
(N95–98%), whereas uninfected bystander cells did not show loss of
PD-1, suggesting that virus replication results in loss of PD-1
expression (Fig. 2A). Next, we assessed whether the amount of
virus production and/or the percentage of productively infected cells
present within the infected milieu alters the expression of PD-1. To
address this we varied the infectivity and number of infected cells
using various amounts of virus inoculum that resulted in 5–20%
infection and assessed PD-1 expression (data not shown). Results
indicate that infected cells lose PD-1 expression irrespective of the
percent EGFP positive cells present within the culture or the amount
of virus produced within an infected cell as measured by EGFP MFI
level (low producers versus high producers). Using multiple donors
(n=15), we compared PD-1 expression between the control cells (no
treatment), productively infected and uninfected bystander cells
present within the infected milieu (Fig. 2B). Compared to the no
treatment control group, productively infected cells exhibit a
signiﬁcant loss of PD-1 (pb0.0001), whereas uninfected bystander
cells showed a slight decrease in PD-1 expression (b3%) that is not
statistically signiﬁcant (p=0.13). As a speciﬁcity control we also
evaluated other cell surface molecules, such as HLA-DR, and CD3
(data not shown) and results indicate no change in these moleculesfurther conﬁrming the speciﬁc effect of virus infection on PD-1
expression.
To rule out whether this phenomenon is not speciﬁc to the
particular strain of HIV-1 (NL43) we used here, PBMC were infected
with several HIV-1 isolates that are CCR5- or CXCR4-receptor utilizing
as well as primary viral isolates from clade A, C and B and assessed for
PD-1 expression. Using p24 (Gag) speciﬁc staining infected and
uninfected cells were separated and PD-1 expression was assessed
within these cells (Fig. 2C). Results indicate that N95% of p24 positive
cells are negative for PD-1 expression, suggesting that virus replica-
tion results in loss of PD-1 and this property is highly conserved across
all HIV-1 viral isolates.
HIV-1 regulates PD-1 expression at the transcriptional level
PD-1 is expressed on T cells that are targets for HIV-1 infection.
HIV-1 viral proteins, Nef and Vpu are known to internalize host cell
surface molecules (CD4, MHC-I) as part of an immune evasive strategy
(Kamp et al., 2000; Piguet et al., 1999). To understand if PD-1 is
internalized during infection and whether this could be the reason for
not detecting PD-1 surface expression, we performed both surface and
intracellular staining of PD-1 by ﬂow cytometry. Results indicate PD-1
is not detected by intracellular staining within the infected cells,
whereas internalized MHC-I was detected (as a positive control)
suggesting that loss of PD-1 surface expression is not due to
internalization (Fig. 3A). These results were further conﬁrmed by
immunoﬂuorescence analysis using PD-1 speciﬁc antibody. While
EGFP+ infected cells did not show PD-1 expression, uninfected cells
exhibited a distinct cell surface expression of PD-1 (Fig. 3B) inmultiple
donors (Fig. 3C), suggesting that internalization is not the cause of PD-
1 loss.
Next to answer whether virus infection regulates PD-1 expression
at the transcriptional level, PD-1 positive cells were sorted and
infected as described before. Forty-eight hours postinfection, an equal
number of EGFP(+) and EGFP(−) cells were sorted and RNA extracted
from these cells were used in a real-time RT-PCR assay. PD-1
transcripts were quantitated in comparison to RLPLO level (Fig. 3D).
Results indicate that EGFP(+) infected cells did not show PD-1
transcripts, whereas an equal number of uninfected cells from the
same culture expressed PD-1 mRNA, suggesting that PD-1 expression
is regulated at the transcriptional level by HIV-1. Additionally, the
internal control, RLPLO did not show any difference within the two
populations (Fig. 3D) suggesting that PD-1 downregulation is speciﬁc
and is not due to cell death or lack of RNA in these cells. Similar results
were observed in multiple donors (n=6).
PD-1 positive cells are highly susceptible to HIV-1 infection
Results presented above indicate that PD-1 expression is fully
abolished in productively infected cells. This led us to ask whether
HIV-1 preferentially infects PD-1 negative cells or infection causes loss
of PD-1. PD-1 positive and PD-1 negative cells were sorted to purity
(shown in Fig. 4A) and infectedwith 0.01MOI of virus and assessed for
infectivity (Fig. 4B). Results indicate that 3 days postinfection, 10% of
the cells in PD-1 positive group are infected, whereas a signiﬁcantly
reduced (20-fold less) infection (b0.67%) was observed in PD-1
negative cells. Similar results were observed in PBMC isolated from
six different donors with varying level of PD-1 expression (Fig. 4C),
suggesting that PD-1 positive cells are preferentially infected byHIV-1.
This could be due to their activation status of target cells as PD-1 is
expressed in activated T cells.
HIV-1 infects activated T cells and virus replication is higher in
activated T cells compared to resting T cells (Chun et al., 2003). To
address whether preferential infection of PD-1 positive cells is due to
the activation status of these cells, we assessed expression of early and
late activation markers such as CD69, CD25 and HLA-DR within the
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that PD-1 positive cells are also highly positive for several activation
markers, suggesting that stimulation increases the expression of PD-1
in CD4+ T cells and these cells are more susceptible to infection
compared to unactivated or resting cells in vitro as reported previously
(Arlen et al., 2006; Yamashita and Emerman, 2006). Additionally, we
also tested the level of viral co-receptors CCR5 and CXCR4 expression
in the PD-1 positive and negative populations and our results indicate
that both populations express viral co-receptors, and that there was
no signiﬁcant difference in the surface expression of CXCR4 in either
PD-1+ or PD-1− cells, when evaluated in multiple donors, though few
donors had higher expression of CCR5 in PD-1 negative cells (Fig. 4E).
Loss of PD-1 in infected cells protects the cells from early apoptosis
Several studies have reported that antigen speciﬁc CD8+/PD-1+ cells
aremore susceptible to spontaneous and induced apoptosis (Dong et al.,
2002; Ishida et al., 1992; Petrovas et al., 2006). To further understand,
whether infected cells (that are PD-1 positive before infection) are re-
sistant to apoptosis, we measured apoptosis in the infected and un-
infected cells by Annexin V staining (Fig. 5A). Results indicate that only
5.6% of virus-infected (EGFP+/PD-1 negative) cells are positive for
Annexin, whereas 23.7% of PD-1 positive bystander cells are positive for
Annexin. A similar scenario was observed in the case of the uninfected
cells also (21.6% in PD-1+ cells) further correlating with the previously
published reports (Ishida et al., 1992; Petrovas et al., 2006).
Viruses are known to protect infected cells from cell death through
upregulation of the anti-apoptotic gene, Bcl-2 (Bahbouhi, Landay, and
Al-Harthi, 2004;Marshall et al.,1999). As infected cells exhibit 50% less
staining for Annexin V, we evaluated for levels of Bcl-2 in infected and
bystander cells (Fig. 5B). Results show that ~65% of infected cells
express detectable level of Bcl-2, compared to 37.7% in bystander cells
in the infected culture, whereas 63% of the cells are positive for Bcl-2 in
the uninfected control. Similar two-fold difference was observed in
multiple donors, suggesting that infected cells express high level of
Bcl-2 during early infection.
PD-1 expression is downregulated within the infected cells in vivo
In HIV-1 infected individuals viral antigen speciﬁc CD8 effector
Tcells express high level of PD-1 that are characteristic of an exhausted
phenotype. This leads to loss of CTL function and directly correlates
with disease progression (Day et al., 2006; Petrovas et al., 2006;
Trautmann et al., 2006). However, expression of PD-1 within the
infected cells in vivo is not known. To further correlate the in vitro
results with in vivo, PBMC were isolated from ten HIV-1 positive
donors and were stained for HIV-1 p24 gag and PD-1 and assessed by
ﬂowcytometry (Fig. 6A; Table 1). HIV-1 positive patientswere selected
randomlyand this population includes patientswith high and lowviral
load, varying CD4 counts and/or antiviral therapy. Consistent with our
in vitro results, infected cells (based on p24+) did not express PD-1
in vivo. Similar results were observed in both freshly isolated and
activated lymphocytes. Results presented in Fig. 6A represent donors
with varying levels of p24 positive cells indicating that p24 positive
cells did not express PD-1, whereas bystander cells exhibit normal PD-
1 level. As PD-1 expression is increased in activated cells,we also tested
the expression of PD-1 from the same donors before and after
activation (Fig. 6A). Together these results for the ﬁrst time indicateFig. 1. PD-1 expression on CD4+ and CD8+ lymphocytes during HIV-1 infection: (A) PBMCwe
expression. Viable lymphocytes were gated based on side scatter and forward scatter dot p
assessed by ﬂow cytometry using directly conjugated antibodies or isotype controls. Number
was evaluated following activation (using α-CD3 and α-CD28) and during the course of HIV-
reporter virus and PD-1 expression on total CD4+ cells was evaluated at regular intervals. Arro
expressing PD-1 in uninfected culture and the grey circles the absolute number of cells exp
percentage of infected cells present at the indicated time points. (C) Effect of AT-2 treated viru
assessed for PD-1 expression. Results represent one of four independent experiments.that productively infected T cells in vivo lose PD-1 as part of their
survival strategy. Next, we assessed Bcl-2 expression within the p24+
cells (infected) obtained from HIV infected donors PBMC (Fig. 6B).
Results indicate that live p24+ cells are also positive for Bcl-2, whereas
p24+ Bcl-2 negative cells are very minimal suggesting that produc-
tively infected cells are protected during virus replication.
Discussion
Viruses utilize several strategies to protect infected cells from
being eliminated by immune responses and other cell-mediated
apoptosis in order to maximize virus replication and survival. HIV-1 is
known to induce both apoptotic and anti-apoptotic signaling in
infected and uninfected bystander lymphocytes (mainly CD4 and CD8
cells) thereby counteracting the antiviral immune response and
effector cell functions (Ameisen, 2001; Gougeon, 2003; Majumder
et al., 2007). In draining lymph nodes of HIV-1 infected individuals,
apoptosis is evident mainly in uninfected bystander cells suggesting
that infected cells may be protected from apoptosis early on as a way
to maximize virus production (Finkel et al., 1995; Ji et al., 2007). HIV-1
gene products such as Nef, Tat and Env are known to play dual roles in
host cell apoptosis by inducing apoptosis in exposed cells, whereas
infected cells are protected from apoptosis (McCloskey et al., 1997;
Moon and Yang, 2006; Seelamgari et al., 2004). Here we report that
HIV-1 infection selectively abolishes PD-1 expression in productively
infected cells thus protecting them from apoptosis, whereas exposed
and/or non-productively infected bystander cells are unaffected in the
in vitro infection model. These results identify an important role for
the PD-1 molecule in virus-infected CD4+ cells and how HIV-1
protects the infected cells from apoptosis during early infection before
lysis. Although, infected cells eventually die or undergo necrosis as a
result of virus infection, our results suggest that PD-1 down regulation
in productively infected cells might protect the cells from spontaneous
and/or activation-induced apoptosis during early infection to increase
virus production.
PD-1 molecule has gained attention in HIV-1 pathogenesis as
increased level of PD-1 is reported in antigen speciﬁc CD8+ and CD4+ T
cells (D'Souza et al., 2007; Petrovas et al., 2007; Trautmann et al.,
2006; Zhang et al., 2007). Although it is not well established how
antigen speciﬁc CD4 and CD8 T cells express high level of PD-1, it is
well accepted that the PD-1molecule has a role in effector cell survival
and blocking PD-1 interaction with PD-L1 restoring the cell function.
As PD-1 is constitutively expressed in all activated T cells and these
activated cells are major producers of HIV-1, we assessed PD-1 ex-
pression in virus-infected cells. Results from this study suggest that
activated cells are preferentially infected by HIV-1, and virus repli-
cation speciﬁcally downregulates PD-1 expression. Additionally, PD-1
downregulation by HIV-1 is not due to internalization or degradation,
but is at the transcriptional level. It is interesting to note that virus
binding, entry or virion-associated proteins do not alter PD-1 ex-
pression (as AT-2 treated virus did not show any change in PD-1 level)
suggesting that the viral transcription machineries might control
PD-1 expression. Though the exact mechanism(s) are unknown it is
reasonable to predict that redirection of transcription factors from
host cellular protein promoters to HIV-1 LTR could be a possibility.
Recently Velu et al. (2007) reported that a high level of PD-1
expression in antigen speciﬁc CD8+ T cells is observed only during
chronic infection, but not in the case of vaccination-induced effectorre infected with HIV-1 EGFP reporter virus and was analyzed by ﬂow cytometry for PD-1
lot. Using the CD3 gating, PD-1 expression on total CD4+ and CD8+ lymphocytes were
s in quadrants indicate percent positive cells. (B) PD-1 expression on CD4+ lymphocytes
1 infection. On day 3 of activation, the cells were washed and infected with HIV-1 EGFP
w indicates the day of infection. The black squares indicate the absolute number of cells
ressing PD-1 in infected culture from the same donor. The solid triangles indicate the
s on PD-1 expression. Activated PBMCwere treated with AT-2 virus (10 and 100 ng) and
Fig. 2. Loss of PD-1 expression on HIV-1 infected lymphocytes: (A) PBMC infected with HIV-1 EGFP reporter virus was analyzed by ﬂow cytometry for PD-1 expression. Viable lymphocytes were gated based on side scatter and forward scatter
dot plot. Using CD3 gating, infected (EGFP+) and bystander (EGFP−) lymphocytes were identiﬁed based on EGFP expression. Expression of PD-1 was assessed by ﬂow cytometry using directly conjugated speciﬁc antibodies or isotype controls.
The expression of PD-1 was analyzed on the infected (EGFP+) and bystander (EGFP−) cells. (B) Loss of PD-1 on infected cells in multiple donors (n=15). p value was derived using paired t test analysis comparing uninfected cells and bystander
cells (⁎), bystander cells and infected cells (⁎⁎) or uninfected and infected cells (⁎⁎). (C) PBMC were infected with primary isolates from clade A, B, C or with lab strains NL43, 89.6. Postinfection (6 days) viable infected cells were identiﬁed by
intracellular p24 and expression of PD-1 was analyzed by ﬂow cytometry. Figure represents one of three independent experiments.
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Fig. 3. HIV-1 regulates PD-1 at the transcriptional level: (A) PBMC infected with HIV-1 EGFP reporter virus were stained for surface expression of CD3, PD-1 or MHC class I molecules and evaluated by ﬂow cytometry. To evaluate further the
internalizedmolecules, the surface stained cells were permeabilized and intra cellular staining of PD-1 andMHC class I was performed asmentioned inMaterials andmethods, and evaluated by ﬂow cytometry. The ﬁgures are representative of
one of the multiple donors (n=6) evaluated. (B) Infected PBMC were ﬁxed with 2% paraformaldehyde and cytospun on to slides, and stained for PD-1, as described in Materials and methods. Infected lymphocytes were detected by direct
ﬂuorescence of EGFP (Green), and the PD-1 was detected using a monoclonal antibody (Red). Nuclei were identiﬁed by DAPI staining (Blue). Arrows in panel (overlay) indicate the presence of PD-1 in the cells. As indicated, the upper panel
shows the uninfected control lymphocytes, and the lower panels show the cells infected with HIV-1 EGFP virus. Results represent one of four independent experiments. (C) Infected cells were identiﬁed by presence of EGFP ﬂorescence and
bystander cells by the absence of EGFP ﬂuorescence. Presence of PD-1 on infected, bystander cells and uninfected control cells was evaluated in ﬁfteen random ﬁelds (50 cells) inmultiple donors (n=6). The percentage of cells expressing PD-1 is
presented. (D) Following activation PD-1(+) cells were sorted and infected with HIV-1-EGFP reporter virus as described. Equal number of infected cells and uninfected cells were sorted and assessed for PD-1 and RLPLO transcripts. Green line
represents EGFP(−) cells and Red line represents EGFP(+) cells. Figure represents one of six experiments using different donor PBMC.
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147N.J. Venkatachari et al. / Virology 376 (2008) 140–153CD8+ Tcells. This important ﬁnding suggests that virus infection per se
has a role in PD-1 dysregulation and clearly distinguishes that
expression of viral antigens by vaccine does not have a role in PD-1
dysregulation. Results from our in vivo data further support this
observation where p24 positive cells did not show PD-1 expression,
whereas bystander cells were not affected.
One possible explanation for this speciﬁc downregulation would
be that HIV-1 might alter PD-1 expression as a method to avoid
activation-induced cell death and maintain the cells in an altered
activated state which assist in virus replication. Though virus-infected
cells are eventually exhausted and die due to the cytopathic effect of
the virus and the lack of host cellular protein transcription, losing PD-
1 on productively infected cells might protect the cells from apoptosis
during early infection and enhance their survival longer thus
increasing virus replication and dissemination. Data from our in vivo
analysis using HIV-1 patients with varying amount of viral load
further support that productively infected cells speciﬁcally lose PD-1
expression, whereas PD-1 level is not affected in bystander cells that
includes both exposed and unaffected cells. This virus-induced effect
is independent of viral strains, clades and co-receptor utilization
indicating that this might a basic function of virus infection. It is not
known whether this phenomenon is speciﬁc to HIV-1 or if other
viruses that target lymphocytes also utilize similar mechanisms.
Published results indicate that an increased level of PD-1
expression in lymphocytes is accompanied by the loss of anti-
apoptotic protein, Bcl-2. Conversely, the loss of PD-1 in infected cells
exhibit elevated the level of Bcl-2 suggesting that a similar apoptotic
pathway is utilized in infected cells. Together, these ﬁndings for theﬁrst time indicate a role of PD-1 in infected T cells during HIV-1
infection and pathogenesis. Identifying the mechanism(s) involved in
the differential regulation of PD-1 in Tcells will provide information to
further understand the multifaceted functions of HIV-1 during
pathogenesis and disease progression.
Materials and methods
Cell culture
PBMCwere isolated by Ficoll–Hypaque gradient centrifugation and
stimulated with anti-CD3 antibody (10 µg/ml) and anti-CD28 anti-
body (1 µg/ml) or with PHA-P (5 µg/ml) for 3 days as described
(Venkatachari et al., 2007) and cultured in growth media containing
rIL-2 (5 U/ml). HEK293T cells were maintained in DMEM containing
10% FBS, 1% L-glutamine and 1% penicillin–streptomycin (GIBCO).
Virus preparation and infectivity
A full length HIV-1 proviral DNA containing Enhanced Green
Fluorescence Protein (EGFP) reporter was constructed as described
(Venkatachari et al., 2007). HEK293T cells (2×106 per plate) were
transfected with 10 µg of HIV-1-EGFP proviral plasmid and virus
preparationwasdone asdescribed (Venkatachari et al., 2007). Virus titer
and multiplicity of infection (MOI) was calculated by ﬂow cytometry
using the HIV-1 reporter cell line cMAGI (AIDS Research and Reference
Reagent Program [RRRP], National Institutes of Health [NIH]). PBMC
were infected with the HIV-1-EGFP reporter virus at a MOI of 0.01.
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were maintained in growth media containing rIL-2 (5 U/ml).
Flow cytometry
Surface staining of the cells was done with CD3, CD4, PD-1, MHC-I,
CCR5, CXCR4, activation markers CD25, CD69, HLA-DR or with isotype
controls as mentioned (Venkatachari et al., 2007). For the detection of
intracellular p24, ﬁxation and permeabilizationwere carried out using
the CytoFix–CytoPerm kit (BD Biosciences, Mountainview, CA) and
intracellular p24 staining was performed at room temperature for 1 h
using 5 µl of anti-p24-FITC antibody (Coulter, Miami, FL; clone KC47)
per 106 cells, followed by twowashes in Perm-Wash buffer, and ﬁnally
resuspended in FACS buffer. Samples were analyzed using Epics-XL
(Beckman Coulter, Miami, FL) with 20,000 to 50,000 gated events
acquired for each sample, and the results were analyzed using FlowJo
software (Tree Star, Inc., OR). Apoptosis was measured using Annexin
V-PE-Cy5 antibody (MBL, Wobourn, MA) and Bcl-2 level was mea-
sured using Bcl-2 speciﬁc antibody according to the manufacturer's
suggestions (BD Biosciences).
Live cell sorting
Normal donor PBMCwere stimulated as described before and CD4+
cells were isolated by negative selection using CD4 isolation Kit II
(Miltenyibiotec, Auburn, CA). Untouched CD4 cells were stained for
PD-1 and, stained cellswere sorted using the high-speed live cell sorter
(FACS Aria, BD Biosciences or MoFlo, Dako cytomation) in IDM or UPCIFig. 4. PD-1 positive lymphocytes aremore susceptible to HIV-1 infection. (A) Normal donor P
(−) cells were sorted and purity of sorted cells was conﬁrmed. (B) Unsorted, PD-1(+) and PD-1
and methods. Percentage of productively infected cells were evaluated in these groups are pr
multiple donors indicate the increased susceptibility (fold difference considering unsorted a
stained for activation markers CD25 and HLA-DR using ﬂorescence tagged monoclonal anti
evaluated by ﬂow cytometry. (E) Expression of HIV-1 co-receptors CXCR4 and CCR5 was evbiocontainment facility according to the standard protocols. Sorted
cells were tested for their purity and cells that are N95% positive or
negative for PD-1 was used for further infection studies. Infected cells
(based on EGFP positive) were sorted using the MoFlo sorter at UPCI
Flow facility with the purity of N98%.
Immunoﬂuorescence
Forty-eight hours postinfection, PBMC were washed with PBS,
and attached onto slides using cytospin. Cells were ﬁxed in 3.7%
formaldehyde at room temperature for 10 min, and washed and
permeabilized with 0.5% Triton X-100 for an additional 10 min. After
washing 3 times with PBS, cells were blocked with 5% BSA at room
temperature for 1 h followed by incubationwith primary antibody (PD-
1; 1:200 dilution, BD Biosciences) for 1 h at room temperature and
incubatedwith rabbit anti-mouse IgGRhodamine (RRX) (1:400; Jackson
ImmunoResearch, West Grove, PA) for 1 h at room temperature. Cells
were mounted with VECTASHIELD mounting media containing DAPI
(Vector Laboratories, Burlingame, CA). Immunoﬂuorescence analysis
was performed using a ﬂuorescence microscope with Nikon SPOT
camera (Fryer, Huntley, IL) and images were processed using Meta-
Morph software (Universal Imaging Corporation, Downington, PA).
Real-time RT-PCR analysis
Equal number (2000 or 5000) of infected and uninfected cells was
sorted using MoFlo cell sorter as described before. Total RNA was
extracted by cell lysis as described (Esumi et al., 2006) and used toBMCwere activated for 3 days, stained for surface expression of PD-1. PD-1(+) and PD-1
(−) sorted cells were infected with HIV-1 EGFP reporter virus as mentioned in Materials
esented. Figure represents one of the multiple donors (n=6) evaluated. (C) Results from
s 1) of PD-1 positive cells for productive infection with HIV-1. (D) Activated PBMC were
bodies and the expression of activation markers in PD-1(+) cells and PD-1(−) cells was
aluated in PD-1(+) and PD-1(−) cells by ﬂow cytometry.
Fig. 4 (continued ).
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Fig. 5. Loss of PD-1 in infected cells reduces the susceptibility of cells to apoptosis: (A) PBMCwere infectedwith HIV-1 EGFP reporter virus as described inMaterials andmethods. Two
days postinfection the cells were stained for CD3, PD-1 and Annexin V, and analyzed by ﬂow cytometry. Viable lymphocytes were gated based on side scatter and forward scatter dot
plot. The CD3 expressing cells were then gated, and the infected (EGFP+) and bystander (EGFP−) cells were identiﬁed based on EGFP expression. The percentage of cells positive for
Annexin V staining in PD-1(+) and PD-1(−) cells was analyzed in both the infected and uninfected control group. (B) Bcl-2 expression in infected and bystander cells. Infected,
bystander and their counterpart uninfected cells were assessed for Bcl-2. Results represent one of six independent experiments.
150 N.J. Venkatachari et al. / Virology 376 (2008) 140–153quantitate RPLPO, PD-1 and HIV-1 gag–pol transcripts by real-time
PCR. Brieﬂy, a two-step RT-PCR was performed as follows: RNA was
reverse transcribed using Taqman Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA); Real-time PCRwas carried out in
triplicate using commercially available primer/probe sets speciﬁc for
PD-1, HIV-1 Gag and ribosomal large protein (RPLPO, Applied
Biosystems). The comparative CT method was used to determine theFig. 6. Loss of PD-1 on infected cells in HIV infected patients: (A) PBMC obtained from HIV
staining for p24 was done using the p24-FITC to detect infected cells. Expression of PD-1 on i
infected cells that are detected at day 0, and the lower panel (Stimulated) represents lympho
infected cells (p24+) obtained from HIV infected donor PBMC. Uninfected donor was used asrelative level of PD-1 transcript by normalizing to the RPLPO control
transcript.
Study population
The study population consisted of 11 HIV-1-infected participants
from the Pittsburgh portion of theMulticenter AIDS Cohort Studywithinfected patients, were evaluated for PD-1 expression by ﬂow cytometry. Intracellular
nfected cells was evaluated on fresh and activated cells. The top panel (Fresh) represents
cytes used on day 4 upon activationwith PHA-P. (B) Bcl-2 expressionwas assessed in the
a control for intracellular staining. Results represent one of three independent donors.
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Table 1
Proﬁle of HIV-1 positive patients used in this study
Sample Years post
Serocon-version
HAART
status
Virus
titer
p24 (%)
positive cells
PD-1 positive
cells (%)
Bystander Infected
71a 4 months Naive 60488 6.7 9.5 2.38
90a 1.5 years Yes b50 – 16.6 N/A
83 2.5 years Yes 319 0.4 6.9 1.46
11 7.5 years Yes 50 2.3 21.0 5.21
53 5.5 years Naive 26724 1.5 10.6 0.06
93 1 year Naive 41355 2.9 9.4 1.3
71b 20 years Yes 50707 2.5 10.9 1.77
90b N20 years Naive 55910 7.5 3.8 0.22
19 4 months Naive 36978 6.0 7.0 1.16
13 6.5 years Naive 16191 3.0 12.8 2.74
152 N.J. Venkatachari et al. / Virology 376 (2008) 140–153viral loads (median, 31,851; range, b50 to 60,488) and their therapy
status (Table 1). The HIV-1 plasma viral load was measured by a
quantitative reverse transcription-PCR assay (Amplicor; Roche Diag-
nostics, Alameda, CA). Blood from HIV-1 positive patients who are
enrolled in the MACS/Pitt's Men Study was collected using an
informed consent form. All IRB protocols were reviewed and approved
by the University of Pittsburgh. PBMC isolated from HIV-1 positive
donors were stained for HIV-1 p24 gag and PD-1 on day 0 (fresh)
as described above and on day 4 following activation with PHA-P
(4 µg/ml) and rIL-2 as described (Arlen et al., 2006) to initiate virus
production.
Statistical analysis
The datawere analyzed using the Student t test for paired samples.
A pvalue of b0.05 was considered signiﬁcant.
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